Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.

Matthew D. Galsky,Romain Banchereau,Habib Rahman Hamidi,Ning Leng,Will Harris,Peter H. ODonnell,Edward E. Kadel,Kobe C. Yuen,D X Jin,Hartmut Koeppen,Darren Tayama,Enrique Grande,Jose Angel Arranz,Maria De Santis,Ian D. Davis,Eiji Kikuchi,Xiaodong Shen,Aristotelis Bamias,Sanjeev Mariathasan

Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.

2020

Matthew D. Galsky
Romain Banchereau
Habib Rahman Hamidi
Ning Leng
Will Harris
Peter H. ODonnell
Edward E. Kadel
Kobe C. Yuen
D X Jin
Hartmut Koeppen
Darren Tayama
Enrique Grande
Jose Angel Arranz
Maria De Santis
Ian D. Davis
Eiji Kikuchi
Xiaodong Shen
Aristotelis Bamias
Sanjeev Mariathasan

5011Background: Tumor mutational burden (TMB), PD-L1 expression, T-effector gene expression (GE) and a fibroblast TGF-β–response signature (F-TBRS) are associated with clinical outcomes with atezo ...

Keywords:

Atezolizumab
urothelial cancer
Immune system
Chemotherapy
Pathology
Stromal cell
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations